CN110934883A - Naringin preparation for improving male osteoporosis and preventing fracture - Google Patents
Naringin preparation for improving male osteoporosis and preventing fracture Download PDFInfo
- Publication number
- CN110934883A CN110934883A CN201911286740.5A CN201911286740A CN110934883A CN 110934883 A CN110934883 A CN 110934883A CN 201911286740 A CN201911286740 A CN 201911286740A CN 110934883 A CN110934883 A CN 110934883A
- Authority
- CN
- China
- Prior art keywords
- naringin
- fructose
- osteoporosis
- bone
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 title claims abstract description 114
- 229930019673 naringin Natural products 0.000 title claims abstract description 114
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 title claims abstract description 114
- 229940052490 naringin Drugs 0.000 title claims abstract description 114
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 229930091371 Fructose Natural products 0.000 claims abstract description 72
- 239000005715 Fructose Substances 0.000 claims abstract description 72
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 72
- 239000003826 tablet Substances 0.000 claims abstract description 29
- 239000000262 estrogen Substances 0.000 claims abstract description 25
- 229940011871 estrogen Drugs 0.000 claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 25
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 19
- 239000011575 calcium Substances 0.000 claims abstract description 19
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 19
- 239000008187 granular material Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 11
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 8
- 235000013361 beverage Nutrition 0.000 claims abstract description 8
- 239000011710 vitamin D Substances 0.000 claims abstract description 8
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 8
- 229940046008 vitamin d Drugs 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 22
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 11
- 239000011647 vitamin D3 Substances 0.000 claims description 11
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 8
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000007935 oral tablet Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 65
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 19
- 230000002829 reductive effect Effects 0.000 abstract description 16
- 229960003604 testosterone Drugs 0.000 abstract description 12
- 239000000047 product Substances 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 7
- -1 flavanone glycoside Chemical class 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 abstract description 2
- 229930003949 flavanone Natural products 0.000 abstract description 2
- 235000011981 flavanones Nutrition 0.000 abstract description 2
- 229930182470 glycoside Natural products 0.000 abstract description 2
- 229960002737 fructose Drugs 0.000 description 58
- 241000699670 Mus sp. Species 0.000 description 21
- 206010065687 Bone loss Diseases 0.000 description 20
- 229960005069 calcium Drugs 0.000 description 17
- 210000001550 testis Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 208000010392 Bone Fractures Diseases 0.000 description 13
- 206010017076 Fracture Diseases 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 210000000689 upper leg Anatomy 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 10
- 210000002997 osteoclast Anatomy 0.000 description 10
- 229960003563 calcium carbonate Drugs 0.000 description 9
- 230000002381 testicular Effects 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000010603 microCT Methods 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 210000000963 osteoblast Anatomy 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 241000736199 Paeonia Species 0.000 description 5
- 235000006484 Paeonia officinalis Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000002379 periodontal ligament Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- CHZJRGNDJLJLAW-RIQJQHKOSA-N (8r,9s,13s,14s,16r,17r)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-16,17-diol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 CHZJRGNDJLJLAW-RIQJQHKOSA-N 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 3
- 102000004067 Osteocalcin Human genes 0.000 description 3
- 108090000573 Osteocalcin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003262 anti-osteoporosis Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 3
- 239000001354 calcium citrate Substances 0.000 description 3
- 229960004256 calcium citrate Drugs 0.000 description 3
- 239000004227 calcium gluconate Substances 0.000 description 3
- 229960004494 calcium gluconate Drugs 0.000 description 3
- 235000013927 calcium gluconate Nutrition 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- 229960002568 ethinylestradiol Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229950007863 nilestriol Drugs 0.000 description 3
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013337 tricalcium citrate Nutrition 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
- 206010002261 Androgen deficiency Diseases 0.000 description 2
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 206010006002 Bone pain Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100037765 Periostin Human genes 0.000 description 2
- 101710199268 Periostin Proteins 0.000 description 2
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 2
- 229960002535 alfacalcidol Drugs 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 201000011529 cardiovascular cancer Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 2
- 229960001023 tibolone Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000674717 Homo sapiens Transcription initiation factor TFIID subunit 7-like Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 102100030590 Mothers against decapentaplegic homolog 6 Human genes 0.000 description 1
- 101710143114 Mothers against decapentaplegic homolog 6 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 1
- 101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 102100021172 Transcription initiation factor TFIID subunit 7-like Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000746 testosterone undecanoate Drugs 0.000 description 1
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000000450 urinary calcium excretion Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
With the increase of age, the testosterone level of middle-aged and elderly men is gradually reduced, the biomechanical performance of bones is reduced, and the fracture and the osteoporosis are easy to occur; the research discovers that a preparation consisting of naringin and fructose can replace testosterone and be used for preventing male osteoporosis and people with reduced bone biomechanical properties, the naringin is a natural flavanone glycoside, the fructose is a special energy supplement, the naringin and the fructose are combined into oral liquid, capsules, tablets, granules, oral liquid and beverages according to the ratio of 1: 3-4, and the preparation can be used for preventing and treating people with reduced bone biomechanical properties caused by various reasons and male osteoporosis patients. The invention also discloses a formula and a production process of the naringin fructose oral liquid, the naringin fructose vitamin D calcium preparation granules, the naringin fructose estrogen tablets and the naringin fructose aspirin tablets, and the products have good effects on preventing male osteoporosis and people with low bone biomechanical function; has better curative effect on female osteoporosis patients.
Description
Technical Field
The invention belongs to the technical field of production of health-care food and medicines, and particularly relates to a naringin preparation for improving male osteoporosis and preventing fracture.
Background
The research shows that the general morbidity of osteoporosis of male population over 50 years old is 22.5%, the incidence rate of bone fracture is 13%, the incidence rate of bone fracture is higher than that of prostatic cancer, the morbidity of osteoporosis in different areas and age stages is different, but the general trend of the development of the general trend of osteoporosis is increased, the medical cost caused by osteoporosis fracture reaches 1.8 trillion (Lin X, etc., Clin Interv Aging, 2015) is expected to reach 2.12 billion, the risk factors of osteoporosis fracture in China are mainly age increase, low body weight, physical activity reduction, smoking, using corticosteroid hormone or androgen ablation therapy, the prevention and treatment of osteoporosis in men are not fully focused on the reduction of bone mass per man and the destruction of bone tissue microstructure of the osteoporosis in men, and the biological performance of the osteoporosis is reduced, the increase, the development of osteoporosis and the related androgen metabolism, the growth, osteoporosis, bone loss, osteoporosis, bone loss, osteoporosis, bone loss, osteoporosis, bone loss, osteoporosis, bone loss, osteoporosis, and other conditions, osteoporosis, bone loss, osteoporosis, bone loss, osteoporosis, and other conditions, Aging, osteoporosis, bone loss, osteoporosis, Aging, osteoporosis, bone loss, osteoporosis, bone loss, Aging, osteoporosis, Aging, osteoporosis, Aging, bone loss, Aging, bone loss, Aging, bone loss, weight.
Naringin is a natural flavanone glycoside, exists in Chinese herbal medicines and citrus fruits, has a definite chemical structure, has been reported to have pharmacological actions of reducing blood fat, calming, resisting inflammation, resisting oxidation, resisting tumors, resisting fungi, resisting atherosclerosis, relieving spasm, easing pain, regulating blood sugar and the like, has an antiallergic action, has an inhibitory action on mutagenicity of heterocyclic amines and the like, has a prevention and treatment effect on gastric ulcer, has an inhibitory action on staphylococcus aureus, salmonella, shigella, escherichia coli and certain fungi, has an antagonistic action on certain poisons, has an effect of improving microcirculation and cartilage histiocyte functions, has effects of reducing capillary permeability and osteoarthropathy rate and the like, and recently, scholars at home and abroad find that naringin has important influence on in-vitro culture of mesenchymal stem cells between mouse bone marrow, osteogenic differentiation of fibroblasts of human periodontal ligament, generation inhibition of osteoclasts and the like, research shows that naringin can increase the expression of osteoblast marker protein (such as osteocalcin, osteopontin, osteoprotegerin and bone morphogenetic protein-2 (BMP-2)), and inhibit the NF-kB and ERK signal transmission activity induced by RANKL (stimulator of nuclear factor-kappa B (NF-kB) ligand (RANKL)) and the protein expression of osteoclast gene, thereby causing osteoclast not to be normally formed, thus playing a role in delaying osteoporosis and promoting the proliferation and differentiation of osteoblast. Bone loss induced in the denervation is associated with the inactivation of Wnt/b catenin, the upregulation of periostin and sclerostin downstream of it. Naringin can up-regulate periostin expression and prevent the decrease of bone density (BMD) induced by nerve excision, and finally the microstructure and mechanical characteristics of bones can not be deteriorated. In addition, naringin can inhibit the differentiation and bone resorption function of osteoclast; inhibit the proliferation activity of osteoclast, and make the expression of RANK, TRAP, MMP-9 and NFATc1 mRNA in the differentiation process of osteoclast down-regulated and the expression of C-fosmRNA up-regulated. This also suggests that naringin may inhibit osteoclast differentiation, proliferation and bone resorption function, and its mechanism may be achieved by inhibiting specific gene expression during osteoclast differentiation. Research on the relationship between naringin and blood vessels in osteoporosis shows that neovascularization is positively correlated with the intake amount and frequency of naringin, hematoxylin-eosin staining shows that the blood vessels are increased and become thick, and VEGF and VEGFR-2 activities are increased in osteoporotic fracture callus, so that naringin is inferred to stimulate the regeneration of blood vessels by regulating a VEGF/VEGFR-2 signal channel of an osteoporosis mouse, and further promote rehabilitation. Further studies have shown that naringin can promote the expression of Vascular Endothelial Growth Factor (VEGF) and Brain Derived Neurotrophic Factor (BDNF) following spinal injury. The naringin is integrated into the nano-stent for repairing osteoporosis, so that the hydrophilicity, the thinness and the fiber uniformity of the stent are improved, the rapid degradation of the stent can be promoted, and the effect of the stent can be better exerted. The study has fixed naringin on chitosan substrate to promote the expression of osteogenic proteins in bone repair, such as type I collagen, bone sialoprotein and osteocalcin. Naringin immobilized on ozonated chitosan substrate, according to Smad1 and Smad6 phosphorylation, is able to activate osteogenic protein Smad signaling by activating Smad receptors and suppressing their inhibitory factors. The scholars also find that the Bmi1 gene of human periodontal ligament stem cells is closely related to the immortality of the human periodontal ligament stem cells, and the over-expression of the Bmi1 gene changes the cell cycle, the cell reproduction and the functionality. Naringin can increase Bmi1 gene expression of human periodontal ligament stem cell, increase activity of alkaline phosphatase, human run-related transcription factor 2 (Runx 2) and osteocalcin, and promote formation of mineral nodule. In addition, naringin also activates and regulates extracellular protein kinase 1/2[ (ERK) 1/2 ]. These results indicate that naringin promotes the role of periodontal ligament stem cell Bmi1 gene in odontogenesis at least through ERK 1/2 cell signaling pathway (jinyuanbao et al, china modern medicine journal 2018). Naringin has also been reported in the literature to inhibit OVX-induced increases in urinary calcium excretion and loss of bone mass and strength in Ovariectomized (OVX) mice, and to improve bone mass in the distal femur, proximal tibia and lumbar spine. Naringin and DF flavonoid components mimic estrogen and inhibit osteoclastogenesis in young retinoic acid-induced osteoporotic rats, probably by modulating OPG and RANKL expression in osteoblasts, naringin has been shown to significantly increase plasma insulin-like growth factor 1 levels, femoral BMD and intensity, BMD in the fifth lumbar and bone calcium concentrations in the femurs and lumbar. Naringin (200 mg/kg oral gavage) has been shown to cause upregulation of BMD, bone volume, trabecular thickness and maximal load in OVX rats. In male rats with intact gonads, naringin has the effect of statins, and can reduce lipid and stimulate the relation between BMP and bone fat. However, the influence of naringin on an animal model with testis removal is not observed at present, whether the naringin can help middle-aged and old-aged osteoporosis patients with male testicular hypofunction is not shown, a method for removing testis is used for establishing an animal model with osteoporosis caused by androgen deficiency for a male, the influence of testosterone and naringin on the reduction of the biomechanical performance of a mouse bone and the osteoporosis caused by androgen deficiency is observed, meanwhile, a series of control medicines which are combined with the naringin and other medicines are designed for observation, and the result shows that the naringin is administrated by gastric irrigation according to 300mg/kg and 600mg/kg solutions for 8 weeks continuously, the bone biomechanical performance of a mouse with testis removal is obviously improved, the osteoporosis is also benefited to a certain extent, and the difference has statistical significance. In the observation of the combination group, we found that the administration of a solution of naringin 300mg/kg + fructose 1200mg/kg through gastric lavage showed better therapeutic effects than naringin alone on various relevant indexes of biomechanical properties of the bone of the testicular-free mice and bone mass loss (see example 1)
The action of the composition is equivalent to that of high-dose naringin, and the fructose is considered to be a special energy supplement, plays an important energy supplement role in the process of replacing androgen by the naringin to prevent bone loss and promote bone formation, enhances the formation of collagen by the naringin, improves the biomechanical property of the bone, and shows that the composition can effectively prevent the occurrence of fracture caused by osteoporosis and is a good medicine for preventing and treating osteoporosis fracture.
Disclosure of Invention
According to the discovery that the preparation consisting of naringin and fructose can prevent osteoporosis caused by sex hormone deficiency after testicle removal, the method for preparing the pharmaceutical preparation or the health food for treating male osteoporosis by using the naringin and the fructose is provided. The combination has a good ratio of 1-2: 3-8 of naringin, and researches prove that the optimal ratio is 1: 4; the medicine preparation consists of 1 part of naringin and 4 parts of fructose, and can be added with a certain excipient to be prepared into clinically applicable oral buccal tablets, oral tablets, capsules, granules, oral liquid and beverages. When the beverage is prepared from naringin fructose, each 1000ml of the beverage contains 1-3 g of naringin and 60-100 g of fructose, and the optimal proportion is that the ratio of naringin to fructose is 1: 2-4.
We also find that calcium carbonate and vitamin D3 can be added into the preparation consisting of naringin and fructose to form a group of health-care food suitable for all kinds of osteoporosis people, and the calcium supplement is an essential precondition in any osteoporosis treatment, can correct negative calcium balance in the bone absorption and bone formation process, and is a material basis for improving bone mass. At present, the recommended value of the element calcium taken by middle-aged and elderly people every day is 1000-1500 mg. The calcium agent mainly applied at present comprises calcium carbonate, calcium lactate, calcium citrate, calcium gluconate, active calcium, amino acid chelated calcium and the like. Vitamin D can promote intestinal calcium absorption and urinary calcium reabsorption, and is prepared from Ginseng radixRegulating with calcium and phosphorus, and promoting calcium precipitation in bone matrix. Vitamin D may also regulate nerve-muscle tissue coordination. The vitamin D3 and the calcium agent are added into the preparation consisting of the naringin and the fructose, so that the anti-osteoporosis activity of the preparation consisting of the naringin and the fructose can be further improved, the biomechanical property of bones can be better improved, and the health food is suitable for various people to take and is used for protecting bones and preventing osteoporosis. The calcium agent provided by the invention is calcium carbonate, calcium lactate, calcium citrate, calcium gluconate, active calcium and amino acid chelated calcium; the vitamin D provided by the invention is vitamin D2, vitamin D3Calcitriol and alfacalcidol. The best product provided by the invention is prepared from naringin, fructose, calcium carbonate and vitamin D3Adding certain excipient, and making into clinically applicable buccal tablet, capsule, tablet, granule, oral liquid and beverage, wherein when the preparation is granule, each tablet contains 30-50 mg of naringin, 100-250 mg of fructose and vitamin D30.1-0.5 ug, 0.3-0.5 g calcium carbonate.
We also find that the preparation consisting of naringin and fructose can also form a new anti-osteoporosis compound with estrogen drugs, and the compound preparations can be used for preventing and treating osteoporosis patients after female menopause; estrogen deficiency is the leading factor in osteoporosis in postmenopausal women, and therefore, estrogen supplementation can be used to treat osteoporosis. Estrogens natural estrogens and synthetic estrogens. The natural estrogen mainly comprises estradiol and estrone. The artificial synthetic estrogen-like substance comprises diethylstilbestrol, ethinyl estradiol, nilestriol and the like. Estrogens bind to osteoblast receptors to promote bone synthesis and remodeling by promoting the release of various cytokines from osteoblasts, and furthermore, estrogens can directly inhibit the bone resorption action of osteoclasts. However, the side effects of estrogen are related to the dosage used, and the lowest dosage recommended to prevent bone mass loss is not suitable for long-term use. Because estrogen is dangerous to induce coronary heart disease, cerebral apoplexy, breast cancer, thromboembolism and other diseases, FDA only applies it as a preventive drug. NIH also advises the cessation of estrogen therapy for osteoporosis, which is considered more disadvantageous. According to the characteristics of the influence of the peony seed oil on the bone biomechanics and the bone quality, the invention provides that the peony seed oil is combined with low-dose estrogen, so that the side effect generated by the estrogen can be reduced while the osteoporosis is prevented. The medicine composition is especially suitable for preventing bone loss of female postmenopausal osteoporosis patients, and has good prevention and treatment effects on climacteric syndromes accompanied by the patients. The estrogen mentioned in the invention refers to estradiol, estrone, diethylstilbestrol, ethinyl estradiol, nilestriol, tibolone (livee) and primimaline (double meili). The combination of the compound of naringin and fructose and low-dose estrogen provided by the invention means that the dose of the estrogen contained in each soft capsule is one third to one half of the dose of the existing estrogen preparation. The best product provided by the invention is an oral tablet prepared from 30-50 mg of naringin and fructose and 0.05-0.01 mg of diethylstilbestrol according to the production process of the tablet, wherein each tablet contains 100-250 mg of the fructose composed of the naringin and the fructose and 0.05-0.01 mg of the diethylstilbestrol.
We also found that the preparation of naringin and fructose can be combined with anti-inflammatory drug aspirin to form a new compound for preventing and treating osteoporosis and bone pain caused by osteoporosis. Our previous studies have demonstrated that aspirin, a cyclooxygenase inhibitor commonly used in the first-class prevention of cardiovascular diseases and cancer, is useful for the first-class prevention of cardiovascular diseases and cancer, and inhibits the synthesis of prostaglandin E2 essential for bone remodeling, has a preventive and therapeutic effect on osteoporosis, and particularly has a superior analgesic effect on pain caused by osteoporosis. This suggests that it may affect the bone health of the user. In vitro studies have shown that aspirin can enhance the survival of bone marrow mesenchymal stem cells (progenitors of osteoblasts) and stimulate differentiation of osteoblasts. Aspirin also inhibits the nuclear factor κ B (NF κ B) pathway and reduces NF receptor activation of expressed κ B ligand, thereby inhibiting osteoclast formation, aspirin may prevent bone loss in an animal model of osteoporosis. Despite the positive impact on bone mineral density, limited human epidemiological studies have shown that aspirin does not reduce the fracture risk. There was a study even mentioning that aspirin increases fracture risk. The current view is that aspirin increases bone mineral density, but its role in fracture prevention is not yet known, and more data is needed to determine the impact of aspirin and bone health on humans. According to the research result of the influence of the peony seed oil on bones, the peony seed oil and aspirin form a compound preparation which can increase bone density, increase ossein, improve the mechanical properties of bones of patients with osteoporosis and prevent fractures. The optimum product of the compound aspirin tablet, which is provided by the invention, can be prepared into tablets for clinical application by adding pharmaceutical auxiliary materials according to the production process of common tablets, wherein each tablet contains 30-50 mg of naringin, 100-250 mg of fructose and 100-500 mg of aspirin.
The following are specific embodiments of the present invention and further description of the technical solutions of the present invention, but the scope of the present invention is not limited to these embodiments, and all changes or equivalent substitutions that do not depart from the spirit of the present invention are included in the scope of the present invention.
Example one
Naringin fructose oral liquid: 30-50 mg of naringin and 100-250 mg of fructose are added into 100-150 mg of drinking water, dissolved, prepared into oral liquid for clinical application according to the production process of the oral liquid, and filled.
The invention relates to a naringin fructose oral liquid: and corresponding pharmaceutic adjuvants can be added according to the requirements of clinical application to prepare capsules, tablets, granules or beverages.
The experimental scheme of the naringin fructose oral liquid for protecting the bone biomechanical function decline and osteoporosis of the testicular-removed mice is as follows: 70 SPF-grade 4-week-old male KM mice are purchased from the center of Experimental animals in Guangdong province, and the license number is SCXK (Guangdong) 2018-. Adaptive feeding for 2 weeks, then evenly dividing into 7 groups according to a random block method, carrying out testicular removal operation in the 6 th week, and beginning intragastric administration of different drugs the next day after operation. Grouping experiments: (1) the sham operation group: performing a pseudo-operation without removing the testis, and beginning to perfuse stomach with normal saline two days after the operation; (2) and (3) removing testis: mice were subjected to bilateral testicular extirpation, epididymis was retained, and after the surgery was completed, the wound was disinfected with iodophor every day until the wound was completely healed. The normal saline for gastric lavage is started two days after the operation; (3) destesticle + testosterone undecanoate: the operation method is the same as that of the testicle removal group, and the gastric lavage testosterone solution (soybean oil is used as a solvent) of 10.4mg/kg is started two days after the operation; (4) removing testis and fructose: the operation method is the same as that of the testicle removal group, and the gastric fructose solution with the concentration of 1200mg/kg is infused in two days after the operation; (5) testicular removal + L naringin: the operation method is the same as that of the testicle removing group, and the administration is started two days after the operation. Feeding naringin solution at a ratio of 300 mg/kg; (6) testicular + H naringin removal: the operation method is the same as that of the testicle removing group, and the administration is started two days after the operation. The naringin solution is infused according to the ratio of 600 mg/kg. Taking a proper amount of naringin raw material medicine, and dissolving the naringin raw material medicine by using 0.9 percent physiological saline solution. (7) Testicle-free + fructose + L naringin (naringin fructose oral liquid): the operation method is the same as that of the testicle removal group, administration is started two days after the operation, and the dosage of the administration by intragastric administration is 300mg/kg of naringin and 1200mg/kg of fructose. Naringin in this study was purchased from Sigma, USA, with a purity of 90.0% or more, and a cargo number N1376. The preparation method comprises the following steps: precisely weighing 3.333g naringin powder in a 50ml volumetric flask, adding sterile normal saline to the scale mark, shaking up to obtain suspension, shaking up before each administration, and then intragastrically administering. Each group of mice was dosed once daily for 8 weeks. In the experiment process, changes of the mice in eating, drinking, activity and the like are observed and recorded every day, the weight is weighed for 1 time in 7 days, and the dosage is adjusted according to the weight change. After the experiment is finished, the left femur is taken, the muscles and the tendons around the femur are removed, the biomechanical indexes of the specimen are detected and analyzed by adopting a Lloyd LR5K Plus bone biomechanical detection system, the experiment adopts a three-point bending method, and the steps are as follows: the left femur of a rat is placed on a testing machine, a pressure head with the diameter of 1mm is used, the loading speed is 2mm/min, the span L is 20mm, the femur is pressurized until fracture occurs, the measurement of a yield point and fracture parameters can be provided, the instrument can record the load (F) and radius (d) change value of each time point in time, a load-displacement curve is drawn, then the maximum load, the fracture load and the elastic load are read, and the rigidity (rigidity coefficient) is calculated. The results of the biomechanical property measurements of the femurs of the experimental mice are shown in table 1.
TABLE 1 Change in bone biomechanical parameters for groups of mice (` C)x±s,n=10）。
As can be seen from the results in Table 1, the maximum load, the elastic load and the rigidity coefficient in the bone biomechanical parameters of the mice in the testicle-removed group are obviously reduced (P is less than 0.05) compared with the mice in the sham operation group; compared with the mouse of the testicle-removing model group, the rigidity coefficient of the testosterone-supplementing group mouse is obviously improved (P is less than 0.01); compared with the testis-removed group, the rigidity coefficient of the fructose group mouse is obviously improved (P is less than 0.05); compared with the mouse with the testis removed group, the L-naringin group mouse has obviously increased breaking load, maximum load, elastic load and rigidity coefficient (P < 0.05). Compared with the testicle-removed group, the elastic load and the rigidity coefficient of the H-naringin group mice are obviously improved (P is less than 0.05); compared with the testis-removed group, the low-dose naringin fructose oral liquid group has the advantages that the breaking load, the maximum load, the elastic load and the rigidity coefficient are obviously increased (P is less than 0.05); the fracture load refers to the plastic strain of bone before fracture, which reflects the plasticity of bone materials, the maximum load reflects the maximum external force which can be borne by bone, the elastic load reflects the maximum deformation length which can be borne by bone in the elastic range, the rigidity coefficient reflects the external hardness of a bone specimen, and the naringin fructose oral liquid group obviously increases the three mechanical properties of the maximum load, the elastic load and the rigidity coefficient of bone, which indicates that the naringin fructose oral liquid group has obvious bone strengthening function, wherein the elastic load of the bone of a mouse treated by the naringin fructose oral liquid group is stronger than that of a mouse treated by testosterone and better than that of the mouse treated by the testosterone alone with high dose, and the naringin fructose oral liquid group is prompted to replace the testosterone to prevent the reduction of the bone mechanical properties caused by androgen reduction.
And (3) carrying out Micro-CT detection on the thighbone of the mouse without the testis by using the naringin fructose oral liquid: muscle and attached tissues of the left femur of the mouse are removed, the mouse is placed into a Micro-CT (Micro-computed tomography) instrument, and the metaphysis of the femur is subjected to X-ray scanning. The viva CT40 selects the scan parameters image matrix 2048X 2048, integration time 200ms, energy/intensity 70kVp, 114 μ A, 8W. Scanning is performed with 0 ° rotation. After the scanning is finished, selecting bone tissues 1.0mm away from the far end of the growth plate and 2.0mm in layer thickness as a cancellous bone interested Region (ROI) for three-dimensional reconstruction, and extracting image information with the lowest threshold value of 150. Quantitative analysis parameters were analyzed using the SCANCOMedical AG software. The parameters are as follows: connection Density (conn.d.), Structural Model Index (SMI), Volume Bone Density (BMD), Bone Volume fraction (Bone Volume/Tissue Volume, BV/TV), Trabecular number (tb.n), Trabecular Thickness (Trabecular thicness, tb.th), Trabecular separation (tb.sp). The results are shown in tables 2 and 3.
TABLE 2 Micro-CT quantitative parameter index Change (1) for each group of micex±s,n=10）。
As can be seen from the results in Table 2, the Micro-CT parameters of the mice in the testicular-free model group showed a significant decrease in the femoral junction density and the number of bone integration, and the structural model index showed a significant increase in the number of bone integration in the mice in the Micro-CT model group, as compared with the mice in the sham operation group (see the following table 2)P<0.05); the integral number of bone parts of the testosterone-supplemented mice is obviously increased and the structural model index is obviously reduced compared with the testicular-removed model mice (the structural model index is obviously reduced) ((P<0.05); compared with the oral liquid group without testis, the naringin fructose oral liquid group has obviously increased femur connection density and bone integration number, and the structural model index is obviously reduced (P<0.05). The Structural Model Index (SMI) reflects the extent of trabecular (plate-like) and rod-like (rod-like) bone, with SMIs for trabecular and rod-like trabecular bone being 0 and 3 in order. In the case of osteoporosis, the trabecular bone changes from plate-like to rod-like and the SMI value increases. The SMI of the testicle-removing model group reaches 3.09, which indicates that the trabecula bone is changed from a plate shape to a rod shape, the osteoporosis appears, and the change of the trabecula bone from a plate shape to a rod shape can be improved by supplementing testosterone or naringin and fructose oral liquidThe bone is in a rod-shaped state, so that the loss of trabecular bone is reduced, the connection density (conn.d) represents the connection number between trabecular networks, the connection density is obviously reduced in the testicular removal model group compared with a sham operation group, and the reduction of the connection number between the trabecular networks of the bone after testicular removal can be prevented by supplementing testosterone or naringin fructose oral liquid; the bone volume fraction is an important index for evaluating bone mass, the number of bone parts of the testicle-removed model group is obviously reduced, which indicates that the bone mass is lost in a large amount, and the number of the bone parts of the testicle-removed model group is obviously increased by supplementing testosterone or naringin fructose oral liquid, which indicates that the two medicines can reduce the bone loss but far cannot reach the level of a control group.
TABLE 3 Micro-CT quantitative parameter index Change (2) for each group of micex±s,n=10）。
As can be seen from the results in Table 3, the number of trabeculae of femur was significantly decreased in the Micro-CT parameter and the trabecular bone separation was significantly increased in the mice of the testicular removal model group compared to the mice of the sham operation group: (P<0.01); the number and thickness of trabeculae are obviously increased and the separation degree of trabeculae is obviously reduced in the testosterone supplementing group mice and the testicular removal model group mice (the separation degree of the trabeculae is obviously reduced: (P<0.05); compared with the mice of the testicle-removed model group, the mice of the naringin fructose oral liquid group have obviously increased number of the trabeculae of the femur and obviously reduced separation degree of the trabeculae (P<0.01). Research results show that naringin fructose oral liquid group has the same effect as testosterone, can obviously increase the number and thickness of trabeculae, reduce the separation degree of the trabeculae and obviously resist the bone loss caused by testicle removal, but compared with a control group, the antagonism still can not reach the level of the control group.
Example two
According to the experimental result of the first embodiment, calcium carbonate and vitamin D3 are added into the naringin fructose preparation to form a group which is better in curative effect and suitable for various osteoporosis peopleA health food for group administration. Calcium supplement for naringin fructose preparation can be calcium carbonate, calcium lactate, calcium citrate, calcium gluconate, active calcium, and amino acid chelated calcium; the vitamin D can be vitamin D, vitamin D2Vitamin D3Calcitriol and alfacalcidol. The best product provided by the invention is composed of peony seed oil, calcium carbonate and vitamin D3The components, the formula and the production process are as follows.
Naringin, fructose and vitamin D calcium preparation granules: selecting appropriate amount of naringin, fructose, and vitamin D3Calcium carbonate is prepared into a formula, then a proper amount of stabilizing agent, antioxidant, suspending agent, emulsifier and other ingredients are added, and then the granules are prepared according to the production process of the granules, wherein each granule comprises 30-50 mg of naringin, 100-250 mg of fructose and fructose, and vitamin D30.1-0.5 ug, 0.3-0.5 g calcium carbonate.
EXAMPLE III
According to the experimental result of the first embodiment, a novel anti-osteoporosis compound is formed by adding estrogen medicines into a naringin fructose preparation, and the compound preparation can be used for preventing and treating female postmenopausal osteoporosis patients, is particularly suitable for preventing bone loss of the female postmenopausal osteoporosis patients and has good prevention and treatment effects on climacteric syndromes accompanied by the patients. The estrogen which can be added in the naringin fructose preparation is estradiol, estrone, diethylstilbestrol, ethinyl estradiol, nilestriol, tibolone (livea) and primeverine (bimesol). The content of each grain of the compound preparation prepared by the naringin fructose estrogen and the estrogens is one third to one half of the pharmaceutical preparation dosage of the estrogens. The formula and production process of the optimal product provided by the invention are as follows.
Naringin fructose estrogen tablets: the preparation method comprises the steps of taking naringin, fructose and diethylstilbestrol, adding a proper amount of a stabilizer, an antioxidant, a suspending agent and an emulsifier, and then preparing the oral tablet according to the production process of the tablet, wherein each tablet contains 30-50 mg of naringin, 100-250 mg of fructose and 0.05-0.01 mg of diethylstilbestrol.
Example four
According to the experimental result of the first embodiment, a novel compound is designed by adding anti-inflammatory aspirin in a naringin fructose preparation, and the compound is used for preventing and treating osteoporosis and bone pain caused by osteoporosis. The optimum product formula and production process of the compound preparation consisting of the naringin fructose preparation and the aspirin are as follows.
The naringin fructose preparation aspirin tablet: naringin, fructose and aspirin are selected, pharmaceutical auxiliary materials are added according to a production process of a common tablet, and the tablet is pressed into a tablet for clinical application, wherein each tablet contains 30-50 mg of naringin, 100-250 mg of fructose and 100-500 mg of aspirin.
The products described in the first, second, third and fourth examples can be prepared into clinically applicable capsules, tablets, granules, oral liquid and beverages by adding excipients.
Claims (5)
1. A group of naringin preparations for improving male osteoporosis and preventing fracture is characterized by containing naringin and fructose in a ratio of 1: 3-4.
2. The naringin preparation for improving male osteoporosis and preventing fracture as claimed in claim 1, wherein appropriate amount of stabilizer, antioxidant, suspending agent and emulsifier can be added when preparing naringin fructose vitamin D calcium granule, and the granule is prepared according to the production process of granule, each of which contains 30-50 mg of naringin, 100-250 mg of fructose, vitamin D30.1-0.5 ug, 0.3-0.5 g calcium carbonate.
3. The group of naringin preparations for improving male osteoporosis and preventing fracture as claimed in claim 1, wherein when preparing the naringin fructose estrogen tablet, the tablet can be prepared into oral tablets according to the production process of the tablet, each tablet contains 30-50 mg of naringin fructose 100-250 mg and 0.05-0.01 mg of diethylstilbestrol.
4. The naringin preparation for improving male osteoporosis and preventing fracture as claimed in claim 1, wherein when preparing naringin fructose aspirin tablet, the tablet can be prepared by adding pharmaceutical auxiliary materials according to the production process of common tablet, and pressing into tablet for clinical application, each tablet contains 30-50 mg of naringin, 100-250 mg of fructose and 100-500 mg of aspirin.
5. The naringin preparation for improving male osteoporosis and preventing fracture as claimed in claim 2-4, further comprising excipients, and can be made into clinically applicable capsule, tablet, granule, oral liquid and beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911286740.5A CN110934883A (en) | 2019-12-14 | 2019-12-14 | Naringin preparation for improving male osteoporosis and preventing fracture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911286740.5A CN110934883A (en) | 2019-12-14 | 2019-12-14 | Naringin preparation for improving male osteoporosis and preventing fracture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110934883A true CN110934883A (en) | 2020-03-31 |
Family
ID=69910727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911286740.5A Pending CN110934883A (en) | 2019-12-14 | 2019-12-14 | Naringin preparation for improving male osteoporosis and preventing fracture |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110934883A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588176A (en) * | 2022-02-15 | 2022-06-07 | 许静宜 | Method for researching promotion of ophiopogonin D on osteoporosis H-type blood vessels |
| WO2023143221A1 (en) * | 2022-01-29 | 2023-08-03 | 暨南大学 | Composition for preventing or treating osteoporosis, preparation thereof and use thereof |
| CN117373681A (en) * | 2023-10-30 | 2024-01-09 | 中国航天科工集团七三一医院 | Fracture healing simulation method and system based on blood glucose regulation system effect |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070116836A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith |
| US20100099640A1 (en) * | 2007-05-04 | 2010-04-22 | Joannes Geuns | Tissue degeneration protection |
| CN105104981A (en) * | 2015-09-17 | 2015-12-02 | 佛山市顺德区宝铜金属科技有限公司 | Food containing shaddock aromas and taste |
| CN108578470A (en) * | 2018-05-23 | 2018-09-28 | 广东永青生物科技有限公司 | The pharmaceutical composition that the hyperthyroid high conversion hysteria bone loss of one group of improvement and bone biomechanical property decline |
| CN108714171A (en) * | 2018-06-09 | 2018-10-30 | 广东永青生物科技有限公司 | Strengthening flesh by the strong bone that fructose and Exocarpium Citri Rubrum form for one group enhances the health food of locomitivity and the formula and processing technology of drug |
-
2019
- 2019-12-14 CN CN201911286740.5A patent/CN110934883A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070116836A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith |
| US20100099640A1 (en) * | 2007-05-04 | 2010-04-22 | Joannes Geuns | Tissue degeneration protection |
| CN105104981A (en) * | 2015-09-17 | 2015-12-02 | 佛山市顺德区宝铜金属科技有限公司 | Food containing shaddock aromas and taste |
| CN108578470A (en) * | 2018-05-23 | 2018-09-28 | 广东永青生物科技有限公司 | The pharmaceutical composition that the hyperthyroid high conversion hysteria bone loss of one group of improvement and bone biomechanical property decline |
| CN108714171A (en) * | 2018-06-09 | 2018-10-30 | 广东永青生物科技有限公司 | Strengthening flesh by the strong bone that fructose and Exocarpium Citri Rubrum form for one group enhances the health food of locomitivity and the formula and processing technology of drug |
Non-Patent Citations (5)
| Title |
|---|
| 李念虎等: "柚皮苷促进成骨细胞分化并有效改善卵巢切除所致的骨质疏松", 《中国骨质疏松杂志》 * |
| 田英著: "《全科医学骨干师资培训教程》", 30 September 2019 * |
| 金元宝等: "柚皮苷的生物活性研究进展", 《中国现代医药杂志》 * |
| 陈朋等: "化橘红中柚皮苷含量近红外定量模型的建立", 《中药材》 * |
| 黄振兴等: "男性骨质疏松症与睾酮关系的研究进展", 《中国骨质疏松杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023143221A1 (en) * | 2022-01-29 | 2023-08-03 | 暨南大学 | Composition for preventing or treating osteoporosis, preparation thereof and use thereof |
| CN114588176A (en) * | 2022-02-15 | 2022-06-07 | 许静宜 | Method for researching promotion of ophiopogonin D on osteoporosis H-type blood vessels |
| CN114588176B (en) * | 2022-02-15 | 2024-01-23 | 许静宜 | Method for researching ophiopogonin D to promote osteoporosis H-type blood vessel |
| CN117373681A (en) * | 2023-10-30 | 2024-01-09 | 中国航天科工集团七三一医院 | Fracture healing simulation method and system based on blood glucose regulation system effect |
| CN117373681B (en) * | 2023-10-30 | 2024-04-26 | 中国航天科工集团七三一医院 | Fracture healing simulation method and system based on blood glucose regulation system effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110934883A (en) | Naringin preparation for improving male osteoporosis and preventing fracture | |
| CN109364194A (en) | It maintains bone health and treats the composition of the osteoarthropathy in osteoarthritis and joint | |
| KR101513855B1 (en) | A composition for the treatment or prevention of osteoarthrits comprising an extract of crinum asiaticum | |
| KR101524230B1 (en) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising lycium root bark extracts | |
| KR101451754B1 (en) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of lycium root bark and dipsacus asper wall | |
| KR101491595B1 (en) | Pharmaceutical composition for promoting osteogenesis containing axial-equatorial aryl-oriented furofuran-type lignan, and pharmaceutical preparation, functional food product, and health food product comprising composition | |
| KR101451755B1 (en) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of Mori Fructus and Aralia Continentalis | |
| US7579374B2 (en) | Agent for improving bone metabolism | |
| CN101401804A (en) | Uses of salvianolic acid B in preparing medicament formulation for preventing and controlling osteoporosis | |
| KR101444760B1 (en) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of Achyranthes bidentata and Siegesbeckia glabrescens | |
| CN110876766A (en) | Application of peony seed oil in preparation of medicines and health-care foods for improving biomechanical properties of male bones | |
| KR20170054115A (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating osteoporosis | |
| JP2021503483A (en) | Composition for prevention, amelioration or treatment of bone loss disease containing CHP (cyclo-hispro) | |
| KR20160057525A (en) | composition for the prevention and treatment ofosteoporosis containing Acyranthes bidentata Blume and ginseng extract | |
| CN115944643A (en) | Application of sialic acid in preparing anti-osteoporosis medicine and food | |
| JP4691039B2 (en) | Composition for prevention and treatment of climacteric disease containing declining horn extract as active ingredient | |
| JP7232503B2 (en) | Pharmaceutical composition for prevention and/or treatment of bone disease | |
| KR102106401B1 (en) | COMPOSITION FOR BONE GROWTH PROMOTING COMPRISING Portulaca oleracea L. AS AN ACTIVE INGREDIENT | |
| KR100597563B1 (en) | Health care foods comprising Eleutheroside E having bone growth-promoting effects | |
| KR20120045122A (en) | Composition for preventing and treating bone diseases comprising arthritis | |
| KR100597564B1 (en) | Pharmacuetical compositions comprising Eleutheroside E having bone growth-promoting effects | |
| CN111991405B (en) | Application of curdione and ginkgoneoic acid in preparation of bone formation promoting medicine | |
| KR20140061825A (en) | Perillae semen extracts for enhancing differentiation of osteoblast and inhibiting differentiation of osteoclast and use of thereof as bone formation promoting products and bone resorption inhibitory products | |
| JP2012158579A (en) | Food, medical product and animal feed for preventing and ameliorating osteoporosis | |
| KR102106400B1 (en) | COMPOSITION FOR BONE GROWTH PROMOTING COMPRISING Sanguisorba officinalis L. AS AN ACTIVE INGREDIENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200331 |
|
| WD01 | Invention patent application deemed withdrawn after publication |